The tear and plasma pharmacokinetics study of TS-1 monotherapy for gastric cancer patients.

Trial Profile

The tear and plasma pharmacokinetics study of TS-1 monotherapy for gastric cancer patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary)
  • Indications Gastric cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 25 Jan 2018 Status changed from active, no longer recruiting to completed.
    • 20 Jan 2018 Results assessing association between tear and plasma concentrations of Tegafur, 5-Fluorouracil, and 5-chloro-2,4-dihydroxypyridine presented at the 2018 Gastrointestinal Cancers Symposium
    • 27 Mar 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top